Rabeprazole sodium 5 mg + Rabeprazole sodium 10 mg + Placebo

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastroesophageal Reflux

Conditions

Gastroesophageal Reflux

Trial Timeline

Nov 1, 2009 → Nov 1, 2011

About Rabeprazole sodium 5 mg + Rabeprazole sodium 10 mg + Placebo

Rabeprazole sodium 5 mg + Rabeprazole sodium 10 mg + Placebo is a phase 3 stage product being developed by Eisai for Gastroesophageal Reflux. The current trial status is completed. This product is registered under clinical trial identifier NCT00992589. Target conditions include Gastroesophageal Reflux.

What happened to similar drugs?

4 of 20 similar drugs in Gastroesophageal Reflux were approved

Approved (4) Terminated (1) Active (16)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00992589Phase 3Completed